Toward imaging of alpha-synuclein with PET.

Kantarci, Kejal · Cell · 2023

editorial · Level V

Where this comes from

Abstract

Development of radiopharmaceuticals for in vivo positron emission tomography imaging of alpha-synuclein aggregates has the potential to revolutionize Lewy body disease diagnosis and treatment. Reporting in this issue of Cell, Xiang et al. developed a high-affinity positron emission tomography tracer for alpha-synuclein.

Medical subject headings